Induction of senescence-associated secretory phenotype underlies the therapeutic efficacy of PRC2 inhibition in cancer
出版年份 2022 全文链接
标题
Induction of senescence-associated secretory phenotype underlies the therapeutic efficacy of PRC2 inhibition in cancer
作者
关键词
-
出版物
Cell Death & Disease
Volume 13, Issue 2, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-02-16
DOI
10.1038/s41419-022-04601-6
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Somatic mutations and single-cell transcriptomes reveal the root of malignant rhabdoid tumours
- (2021) Lars Custers et al. Nature Communications
- Mechanisms of Macrophage Plasticity in the Tumor Environment: Manipulating Activation State to Improve Outcomes
- (2021) Tiffany Davia Ricketts et al. Frontiers in Immunology
- Senescent mesenchymal stem cells remodel extracellular matrix driving breast cancer cells to a more-invasive phenotype
- (2020) Deepraj Ghosh et al. JOURNAL OF CELL SCIENCE
- SciPy 1.0: fundamental algorithms for scientific computing in Python
- (2020) Pauli Virtanen et al. NATURE METHODS
- Cytokine-Induced Guanylate Binding Protein 1 (GBP1) Release from Human Ovarian Cancer Cells
- (2020) Grazia Carbotti et al. Cancers
- The SWI/SNF complex in cancer — biology, biomarkers and therapy
- (2020) Priya Mittal et al. Nature Reviews Clinical Oncology
- Drugging histone methyltransferases in cancer
- (2020) Laia Richart et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Classical and Nonclassical Intercellular Communication in Senescence and Ageing
- (2020) Juan Antonio Fafián-Labora et al. TRENDS IN CELL BIOLOGY
- Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study
- (2020) Mrinal Gounder et al. LANCET ONCOLOGY
- Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
- (2020) Franck Morschhauser et al. LANCET ONCOLOGY
- Cellular Senescence Variation by Metabolic and Epigenomic Remodeling
- (2020) Mitsuyoshi Nakao et al. TRENDS IN CELL BIOLOGY
- Senescent cells and macrophages: key players for regeneration?
- (2020) Sonia S. Elder et al. Open Biology
- L1 drives IFN in senescent cells and promotes age-associated inflammation
- (2019) Marco De Cecco et al. NATURE
- R-Loops Enhance Polycomb Repression at a Subset of Developmental Regulator Genes
- (2019) Konstantina Skourti-Stathaki et al. MOLECULAR CELL
- PRC2 is high maintenance
- (2019) Jia-Ray Yu et al. GENES & DEVELOPMENT
- Molecular Mechanisms Directing PRC2 Recruitment and H3K27 Methylation
- (2019) Anne Laugesen et al. MOLECULAR CELL
- An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer
- (2019) Marian L. Burr et al. CANCER CELL
- Basement membrane collagens and disease mechanisms
- (2019) Anna Gatseva et al. Essays in Biochemistry
- Cellular Senescence: Defining a Path Forward
- (2019) Vassilis Gorgoulis et al. CELL
- Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas
- (2019) Makoto Yamagishi et al. Cell Reports
- Binding Modes of Small‐Molecule Inhibitors to the EED Pocket of PRC2
- (2019) Dading Huang et al. CHEMPHYSCHEM
- Development and Validation of an RNA-Seq-Based Prognostic Signature in Neuroblastoma
- (2019) Jian-Guo Zhou et al. Frontiers in Oncology
- KDM6B counteracts EZH2-mediated suppression of IGFBP5 to confer resistance to PI3K/AKT inhibitor treatment in breast cancer
- (2018) Wenyu Wang et al. MOLECULAR CANCER THERAPEUTICS
- Regulation of Cellular Senescence by Polycomb Chromatin Modifiers through Distinct DNA Damage- and Histone Methylation-Dependent Pathways
- (2018) Takahiro Ito et al. Cell Reports
- Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors
- (2018) Xun Huang et al. CELL
- The dynamic nature of senescence in cancer
- (2018) Soyoung Lee et al. NATURE CELL BIOLOGY
- 20(S)-Ginsenoside Rh2 suppresses proliferation and migration of hepatocellular carcinoma cells by targeting EZH2 to regulate CDKN2A-2B gene cluster transcription
- (2017) Qi Li et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2
- (2017) Liying Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models
- (2017) Elayne Chan-Penebre et al. MOLECULAR CANCER THERAPEUTICS
- An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED
- (2017) Wei Qi et al. Nature Chemical Biology
- EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas
- (2017) Faizaan Mohammad et al. NATURE MEDICINE
- Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2
- (2017) Lian Dee Ler et al. Science Translational Medicine
- EZH2 enables germinal centre formation through epigenetic silencing of CDKN1A and an Rb-E2F1 feedback loop
- (2017) Wendy Béguelin et al. Nature Communications
- Acquired Tissue-Specific Promoter Bivalency Is a Basis for PRC2 Necessity in Adult Cells
- (2016) Unmesh Jadhav et al. CELL
- MLL1 is essential for the senescence-associated secretory phenotype
- (2016) Brian C. Capell et al. GENES & DEVELOPMENT
- Expression of ANRIL-Polycomb Complexes-CDKN2A/B/ARF Genes in Breast Tumors: Identification of a Two-Gene (EZH2/CBX7) Signature with Independent Prognostic Value
- (2016) D. Meseure et al. MOLECULAR CANCER RESEARCH
- Naturally occurring p16Ink4a-positive cells shorten healthy lifespan
- (2016) Darren J. Baker et al. NATURE
- An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation
- (2016) George P Souroullas et al. NATURE MEDICINE
- deepTools2: a next generation web server for deep-sequencing data analysis
- (2016) Fidel Ramírez et al. NUCLEIC ACIDS RESEARCH
- BRD4 Connects Enhancer Remodeling to Senescence Immune Surveillance
- (2016) N. Tasdemir et al. Cancer Discovery
- PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer
- (2015) Nisha Nagarsheth et al. CANCER RESEARCH
- Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
- (2015) Dongjun Peng et al. NATURE
- The DNA damage response induces inflammation and senescence by inhibiting autophagy of GATA4
- (2015) C. Kang et al. SCIENCE
- Senescence-associated inflammatory responses: aging and cancer perspectives
- (2015) Audrey Lasry et al. TRENDS IN IMMUNOLOGY
- Inhibition of histone methyltransferase EZH2 depletes leukemia stem cell of mixed lineage leukemia fusion leukemia through upregulation of p16
- (2014) Koki Ueda et al. CANCER SCIENCE
- Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma
- (2014) S. K. Knutson et al. MOLECULAR CANCER THERAPEUTICS
- MiR-138 Induces Renal Carcinoma Cell Senescence by Targeting EZH2 and Is Downregulated in Human Clear Cell Renal Cell Carcinoma
- (2014) Jiaqian Liang et al. ONCOLOGY RESEARCH
- featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
- (2013) Y. Liao et al. BIOINFORMATICS
- EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation
- (2013) Wendy Béguelin et al. CANCER CELL
- A Senescence-Inflammatory Switch from Cancer-Inhibitory to Cancer-Promoting Mechanism
- (2013) Ariel Pribluda et al. CANCER CELL
- Chromatin modifiers and remodellers: regulators of cellular differentiation
- (2013) Taiping Chen et al. NATURE REVIEWS GENETICS
- Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2
- (2013) S. K. Knutson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- EZH2 Regulates the Expression of p16 in the Nasopharyngeal Cancer Cells
- (2013) Jing Zhong et al. TECHNOLOGY IN CANCER RESEARCH & TREATMENT
- Twist-1 Induces Ezh2 Recruitment Regulating Histone Methylation along the Ink4A/Arf Locus in Mesenchymal Stem Cells
- (2012) D. Cakouros et al. MOLECULAR AND CELLULAR BIOLOGY
- EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
- (2012) Michael T. McCabe et al. NATURE
- A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells
- (2012) Sarah K Knutson et al. Nature Chemical Biology
- Fast gapped-read alignment with Bowtie 2
- (2012) Ben Langmead et al. NATURE METHODS
- Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation
- (2012) W. Qi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications
- (2011) Felix Krueger et al. BIOINFORMATICS
- Tumor Suppressor and Aging Biomarker p16INK4aInduces Cellular Senescence without the Associated Inflammatory Secretory Phenotype
- (2011) Jean-Philippe Coppé et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The Polycomb complex PRC2 and its mark in life
- (2011) Raphaël Margueron et al. NATURE
- Epigenetic Antagonism between Polycomb and SWI/SNF Complexes during Oncogenic Transformation
- (2010) Boris G. Wilson et al. CANCER CELL
- Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin
- (2010) Ryan D Morin et al. NATURE GENETICS
- Polycomb protein Ezh2 regulates pancreatic -cell Ink4a/Arf expression and regeneration in diabetes mellitus
- (2009) H. Chen et al. GENES & DEVELOPMENT
- Ndy1/KDM2B immortalizes mouse embryonic fibroblasts by repressing theInk4a/Arflocus
- (2009) Alexandros Tzatsos et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started